Huda Y. Zoghbi

Board Director

Director

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 1 saleSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€554k

Latest filing published 12 Aug 2026 for Regeneron Pharmaceuticals, INC., €554k. Read the official filing

Filing timeline

BuySale

Huda Y. Zoghbi

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Huda Y. Zoghbi: trading record in brief

Huda Y. Zoghbi (board member) discloses dealings in Regeneron Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 13 September 2021 to 10 August 2026, the count stands at 11 filings.

The open-market record consists of 1 sale worth €554k, with no purchase. Outside the open market, there are 4 share grants and 6 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

The latest filing, published on 12 August 2026, reports an open-market sale of €554k in Regeneron Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.